An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Jyoti Wadhwa ( Moderator ) ,Dr Atul Sharma ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Srujna Joga ( Expert Panel )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Efficient Management of First line ALK-rearranged NSCLC

In this webinar, a detailed discussion is done on the efficient management of first line ALK rearranged NSCLC.

Speakers : Dr B K ,Dr Abhishek Kakroo ,Dr Jogamaya Pattnaik

Efficient Management of First line ALK-rearranged NSCLC - Part V

Explore optimal first-line strategies for ALK-rearranged NSCLC to enhance survival and manage resistance.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part IV

Explore optimal first-line strategies and targeted therapies for managing ALK-rearranged non-small cell lung cancer.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part III

Explore optimal first-line strategies for managing ALK-rearranged NSCLC with advanced targeted therapies and clinical insights.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part II

Discover effective first-line strategies for managing ALK-rearranged NSCLC using targeted therapies and personalized treatment approaches.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part VI

In this webinar, a detailed discussion is done on the efficient management of first line ALK rearranged NSCLC.

Speakers : Dr Jogamaya Pattnaik

Efficient Management of First line ALK-rearranged NSCLC - Part VII

Explore first-line management strategies and targeted therapies for ALK-rearranged NSCLC to optimize patient outcomes.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti


Recommended News For You

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

PSMA-PET/CT Detects Metastatic Prostate Cancer Missed by Other Imaging

How artificial intelligence could significantly improve the prognosis for cancer patients.

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

Significant differences in breast cancer care still exist, but surgeons can change.

Novel radiotracer identifies biomarker for triple-negative breast cancer

Atezolizumab Consolidation Impresses in High-Risk DLBCL

Recommended Articles For You

Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies 

Understanding SVR Normal Range: A Guide to Achieving Optimal Health 

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition 

Unmasking the Hidden Symptoms of Ovarian Cancer 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Combo Therapy Boosts Early CML Response but Not Long Term

2.

PNH With Extravascular Hemolysis Approves Factor D Inhibitor.

3.

In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.

4.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

5.

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

1.

Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future

2.

Decoding Hamartomas: Understanding Their Causes and Symptoms

3.

Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms 

4.

Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era

5.

Breaking Barriers: Innovative Approaches in Brain Tumor Treatment

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

3.

Efficient Management of First line ALK-rearranged NSCLC

4.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

5.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot